Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical tetrahydrobiopterin for hard-to-heal wounds
ChiCTR2600133912Phase 4Recruiting
- Sponsor
- Nuclear Industry 416 Hospital
- Start
- Dec 2025
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sapropterin in Chronic wound, diabetic foot ulcer (DFU), decubitus ulcer and 3 more (2 arms), sponsored by Nuclear Industry 416 Hospital. Primary endpoint: Complete healing rate of the target wound at Week 12. Started Dec 2025; status: recruiting.
02
Drugs
sapropterin
03
Conditions
Chronic wounddiabetic foot ulcer (DFU)decubitus ulcerstasis ulcerradiodermatitis
Beyond the preview
Go deeper on ChiCTR2600133912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133912.